UNLABELLED: We demonstrated previously that human B-cell lymphomas were effectively and specifically killed in vitro by an antibody to CD74 (LL1) linked to (111)In or other Auger electron emitters. This study was intended to more accurately compare the potency and specificity of 3Auger electron emitters, (111)In, 67Ga, and 125I, and to evaluate beta-particle emitters, 131I and 90Y. The unique property of LL1 is its high level of intracellular uptake. METHODS: Raji B-lymphoma cells were incubated with serial dilutions of the radiolabeled Abs for 2 d and then monitored for cell growth by 2 assays: a cell counting assay and a clonogenic assay. The uptake of radioactivity per cell was monitored at various time points, and the radiation dose was calculated using published S values for radioactivity located in the cytoplasm. Both specific and nonspecific toxicity were evaluated. RESULTS: The beta-particle emitters had considerably higher levels of nonspecific toxicity than the Auger electron emitters, but both 131I and 90Y, and particularly 131I, still had high levels of specificity. Both of these results were consistent with dosimetry calculations. Relative to the delivered disintegrations per cell, 131I and 67Ga were the most potent of the radionuclides tested, with 125I and (111)In being significantly weaker and 90Y being intermediate. The high potency of 67Ga, together with its low nonspecific toxicity, caused this radionuclide to have the highest specificity index. CONCLUSION: When delivered by Ab LL1, both Auger electron and beta-particle emitters can produce specific and effective toxicity. The choice of the optimal radionuclide for therapy may depend on the ease and efficiency of labeling, the specific activity obtained, the nature of the tumor being targeted, and other factors, but the high specificity indices of the Auger electron emitters may be an advantage.
UNLABELLED: We demonstrated previously that human B-cell lymphomas were effectively and specifically killed in vitro by an antibody to CD74 (LL1) linked to (111)In or other Auger electron emitters. This study was intended to more accurately compare the potency and specificity of 3Auger electron emitters, (111)In, 67Ga, and 125I, and to evaluate beta-particle emitters, 131I and 90Y. The unique property of LL1 is its high level of intracellular uptake. METHODS: Raji B-lymphoma cells were incubated with serial dilutions of the radiolabeled Abs for 2 d and then monitored for cell growth by 2 assays: a cell counting assay and a clonogenic assay. The uptake of radioactivity per cell was monitored at various time points, and the radiation dose was calculated using published S values for radioactivity located in the cytoplasm. Both specific and nonspecific toxicity were evaluated. RESULTS: The beta-particle emitters had considerably higher levels of nonspecific toxicity than the Auger electron emitters, but both 131I and 90Y, and particularly 131I, still had high levels of specificity. Both of these results were consistent with dosimetry calculations. Relative to the delivered disintegrations per cell, 131I and 67Ga were the most potent of the radionuclides tested, with 125I and (111)In being significantly weaker and 90Y being intermediate. The high potency of 67Ga, together with its low nonspecific toxicity, caused this radionuclide to have the highest specificity index. CONCLUSION: When delivered by Ab LL1, both Auger electron and beta-particle emitters can produce specific and effective toxicity. The choice of the optimal radionuclide for therapy may depend on the ease and efficiency of labeling, the specific activity obtained, the nature of the tumor being targeted, and other factors, but the high specificity indices of the Auger electron emitters may be an advantage.
Authors: Il Minn; Ying Chen; Ana P Kiess; Robert Hobbs; George Sgouros; Ronnie C Mease; Mrudula Pullambhatla; Colette J Shen; Catherine A Foss; Martin G Pomper Journal: J Nucl Med Date: 2015-07-16 Impact factor: 10.057
Authors: Eftychia Koumarianou; Tatiana A Slastnikova; Marek Pruszynski; Andrey A Rosenkranz; Ganesan Vaidyanathan; Alexander S Sobolev; Michael R Zalutsky Journal: Nucl Med Biol Date: 2014-04-02 Impact factor: 2.408
Authors: Muhamad Faiz Bin Othman; Elise Verger; Ines Costa; Meena Tanapirakgul; Margaret S Cooper; Cinzia Imberti; Valerie J Lewington; Philip J Blower; Samantha Y A Terry Journal: Nucl Med Biol Date: 2019-12-13 Impact factor: 2.408
Authors: Tatiana A Slastnikova; Eftychia Koumarianou; Andrey A Rosenkranz; Ganesan Vaidyanathan; Tatiana N Lupanova; Alexander S Sobolev; Michael R Zalutsky Journal: EJNMMI Res Date: 2012-10-29 Impact factor: 3.138
Authors: Hwan Lee; Aladdin Riad; Paul Martorano; Adam Mansfield; Minu Samanta; Vandana Batra; Robert H Mach; John M Maris; Daniel A Pryma; Mehran Makvandi Journal: J Nucl Med Date: 2019-11-01 Impact factor: 11.082